九洲药业(603456) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter reached CNY 1,289,540,392.43, representing a year-on-year increase of 7.37%[3] - Total profit for the quarter was CNY 259,492,598.49, reflecting a significant increase of 35.27% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 221,821,465.85, up 42.30% year-on-year[3] - The net profit after deducting non-recurring gains and losses was CNY 220,087,823.44, which is a 46.42% increase compared to the previous year[3] - The basic earnings per share for the quarter was CNY 0.25, an increase of 47.06% year-on-year[3] - The diluted earnings per share also stood at CNY 0.25, reflecting the same growth rate of 47.06%[3] - Total operating revenue for the first three quarters of 2025 reached ¥4,160,487,725.65, an increase of 4.9% compared to ¥3,965,261,223.17 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was ¥748,674,344.04, representing a 18.3% increase from ¥632,852,491.81 in 2024[20] - Total comprehensive income for the period reached CNY 752,435,984.63, an increase from CNY 628,981,441.03 in the previous period, representing a growth of approximately 19.6%[21] - Basic and diluted earnings per share increased to CNY 0.84, up from CNY 0.70, reflecting a growth of 20%[21] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was CNY 1,342,005,039.49, showing a substantial increase of 105.19%[3] - The company's cash and cash equivalents as of September 30, 2025, amount to ¥2,711,755,187.41, a decrease from ¥2,748,870,915.99 at the end of 2024[15] - The company has a total of 5,518,729,793.69 in current assets as of September 30, 2025, down from 6,071,494,807.15[15] - Net cash flow from operating activities for the first three quarters of 2025 was CNY 1,342,005,039.49, compared to CNY 654,028,177.61 in the same period of 2024, indicating a significant increase of approximately 104%[23] - Cash inflows from operating activities totaled CNY 4,725,571,418.11, up from CNY 3,947,477,914.32, marking an increase of about 19.6%[23] - Cash outflows from operating activities were CNY 3,383,566,378.62, compared to CNY 3,293,449,736.71 in the previous year, showing an increase of approximately 2.7%[23] - The ending cash and cash equivalents balance was CNY 2,567,368,061.39, slightly down from CNY 2,498,290,974.92 in the previous year[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 59,157[10] - Zhejiang Zhongbei Jiuzhou Group Co., Ltd. holds 31.88% of shares, totaling 283,518,812 shares[10] - The top ten shareholders include four individuals who are considered acting in concert, indicating potential influence on company decisions[11] - The company has not engaged in any share lending or borrowing activities during the reporting period[11] Liabilities and Equity - Total liabilities decreased to ¥1,894,528,281.50 from ¥2,517,671,243.17, reflecting a reduction of approximately 25%[17] - The company's equity attributable to shareholders increased to ¥8,755,178,673.48 from ¥8,536,673,816.75, showing a growth of 2.6%[18] Investments and Acquisitions - The company completed the acquisition of 100% equity in Hangzhou Zhuliang Pharmaceutical Technology Co., Ltd. for ¥22,193,000 on September 18, 2021[12] - The company plans to dissolve the joint venture Zhejiang Shangyao Jiuzhou Biopharmaceutical Co., Ltd. by September 2025, which will not impact the consolidated financial statements[13][14] Research and Development - Research and development expenses for the first three quarters were ¥194,755,936.65, down from ¥240,137,612.13, indicating a decrease of 18.8%[19] Non-Current Assets - The total non-current assets increased to ¥5,200,007,694.16 from ¥5,055,759,255.69, marking a growth of 2.9%[18] Accounting Practices - The company will not apply new accounting standards starting from 2025, maintaining its current accounting practices[26]